摘要
应用双弹头免疫导向治疗药物１３１Ｉ－抗ＡＦＰＭｃＡｂＭＭＣ进行荷人原发性肝癌棵鼠的体内放射免疫显像（ＲＩＩ）及放射免疫治疗（ＲＩＴ）研究。药物经腹腔给予后，第３ｄ即能选择性的定位于肿瘤；第１３ｄ抑瘤率高达８１．５％，远高于单纯１３１Ｉ－抗ＡＦＰＭｃＡｂ组和ＭＭＣ组（分别为２９．６％和１１．１％），提示该药物对人原发性肝癌细胞的亲和力好、杀伤力强，为其进入临床治疗提供了依据。
The study on radioimmunoimaging (RII) and radioimmunotherapy (RIT) for nude mice bearing human primary hepatic cancer(PHC) was preformed,using 131I-anti-AFP McAbMMC, which was a "Dual Warhead"RIT drug. After injection of 131I-anti-AFP McAb-MMC intraperitoneally(IP), selective accumulation was observed in tumor sites of nude mice bearing PHC on day 3 and the tumor growth inhibition rate was 81. 5% on day 13, higher than that in control groups.It suggests that this drug has a better affinity and stronger killing to human primary hepatic cancer cells.
出处
《细胞与分子免疫学杂志》
CSCD
1996年第3期43-45,共3页
Chinese Journal of Cellular and Molecular Immunology
基金
国家"八五"科技攻关资助
